Browse by category

In 2025, approximately 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these

Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...

Amgen revealed new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist...

Once-weekly subcutaneous semaglutide (2.4mg) is more effective on weight loss in conjunction with counselling and physical activity vs...